Debbie Rigby takes a look at the latest in research news
An international survey among pharmacists in 18 countries, including Australia, has shown that pharmacists felt more confident in supporting patients receiving VKAs compared to the more recently introduced NOACs. The authors conclude that education of pharmacists in anticoagulation is essential for improved pharmaceutical patient care.
International Journal of Clinical Pharmacy 2017;39(6):1282-90.
Results from the Tasmanian Atrial Fibrillation (TAF) study show a low overall rate of bleeding in 2202 patients receiving antithrombotic therapy. The combined incidence of major and minor bleeding was significantly higher in warfarin- versus direct-acting oral anticoagulants (DOAC)- and antiplatelet-treated patients. Increasing age, prior bleeding, warfarin and multiple antithrombotic therapies were independently associated with bleeding.
European Journal of Clinical Pharmacology 2017;73(12):1681-9.
In a cohort of 183 postmenopausal women who had either discontinued or continued bisphosphonates after first-line therapy, the risk of new clinical fractures was 40% higher in subjects who took a bisphosphonate drug holiday. The optimal treatment duration for bisphosphonates remains unclear. Careful risk/benefit assessment is mandatory when considering treatment continuation.
Osteoporosis International 2017;28(12):3431-8.
The results of interviews and focus groups with 74 mental health consumers and carers across three Australian states suggests the information needs of mental health consumers and carers remain largely unmet within Australian community pharmacy. This was particularly evident regarding the provision of information about adverse effects of medicines.
International Journal of Pharmacy Practice 2017;25(6):454-62.